Navigation Links
Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.

CINCINNATI, Nov. 2 /PRNewswire/ -- Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label. Fexofenadine HCl and pseudoephredrine HCl extended-release tablets and ergocalciferol capsules represent the first two products launched in the U.S. by Winthrop U.S. under the Winthrop label with Prasco providing sales support and distribution services to Winthrop U.S. Prasco expects to begin shipping the products immediately. Specific financial terms of the agreements were not disclosed.

"We are especially proud to expand our relationship with sanofi-aventis U.S., and we are certainly pleased to provide pharmacists and consumers with these authorized generic options," said Prasco Chief Executive Officer E. Thomas Arington. "Consumers and pharmacists can have confidence in their prescription drug choices, when they have the identical product, quality, reliability of supply and the identical experience that only the brand can provide."

ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis.

About Prasco

Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience. The company's business model encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers. Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and warehouse facility including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit

SOURCE Prasco Laboratories

SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
2. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
3. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
5. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
6. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
7. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
8. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
9. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
10. Clinical Logistics Enters Partnership with Gentris Corporation
11. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Post Your Comments:
(Date:10/13/2015)... 2015  The spine division of Zimmer Biomet (NYSE ... will showcase its portfolio of innovative clinical solutions and ... meeting, October 14-17, 2015, in Chicago ... events: "Supplemental MIS Fixation Options for LLIF" ... 12:30 – 1 p.m. --> "Supplemental MIS ...
(Date:10/13/2015)...  Human Longevity, Inc. (HLI), the genomics-based, technology-driven company ... the launch of the company,s first Health Nucleus, a ... to transform healthcare. The inaugural Health Nucleus is located ... HLI,s headquarters facility. More Health Nucleus facilities are slated ... cities. --> --> ...
(Date:10/13/2015)... Oct. 13, 2015  Synapse Biomedical Inc. ( ... Study (PAS) studying the use of the NeuRx ® ... to enroll patients. the United States ... FDA market-approved criteria. The PAS study group met their ... The study has since expanded the enrollment target to ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Element Blue ™, a leading ... company, RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom ... approach for customers requiring sensor hardware for critical data environments. , RightSensor™, working ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... Dr. ... by Medical New Today on September 18, 2015. The research, which was conducted at ... Dr. Wael Sabbah and colleagues, show connections between stress during pregnancy and future dental ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have an ... has joined with Global Dental Relief (GDR) to help bring dental care ... SmileCareClub will donate one clinic visit to a child in Kenya. , “When SmileCareClub ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... in McHenry County, Illinois with more than 59,000 emergency department visits per year, ... system (EDIS) from T-System, to help improve clinical, operational and financial outcomes. ...
Breaking Medicine News(10 mins):